Pomaglumetad Effects on Glutamate Biomarkers

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

April 28, 2018

Study Completion Date

May 25, 2018

Conditions
Healthy Controls
Interventions
DRUG

POMA

"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"

DRUG

placebo

matching placebo tablets

Trial Locations (4)

10016

New York University, New York

10032

Columbia University, New York

35233

University of Alabama, Birmingham, Birmingham

90095

University of California, Los Angeles, Los Angeles

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT02919774 - Pomaglumetad Effects on Glutamate Biomarkers | Biotech Hunter | Biotech Hunter